1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Bestrophinopathy: new trials by email Literature Review of Bestrophinopathy trials Research Report on Bestrophinopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) OPGx-BEST1 - ARB, BVMD | Phase 1 / Phase 2 | Recruiting | Opus Genetics, Inc | 10 | 2025-09-25 | 2026-09-24 |
| Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases. Retinal Disease, Bestrophinopathy | Completed | Mayo Clinic | 48 | 2014-02-01 | 2023-01-09 |
Vitelliform Macular Dystrophy (2) · Eye Diseases (1) · Retinal Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Macular Degeneration (2) · Retinal Degeneration (2) · Eye Diseases (1) · Retinal Diseases (1)
Mayo Clinic (1) · Opus Genetics, Inc (1)
United States (2)
Alan D. Marmorstein, Ph.D. (1) · Raymond Iezzi, M.D. (1) · Sophie J. Bakri, M.D. (1)
U01EY030547 (1)